Head-To-Head Review: Catamaran (NASDAQ:CTRX) vs. Its Peers

Catamaran (NASDAQ: CTRX) is one of 13 public companies in the “Managed Health Care” industry, but how does it contrast to its competitors? We will compare Catamaran to similar companies based on the strength of its earnings, analyst recommendations, dividends, risk, profitability, institutional ownership and valuation.


This table compares Catamaran and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Catamaran 1.66% 6.54% 4.25%
Catamaran Competitors 1.83% 11.42% 3.50%

Earnings & Valuation

This table compares Catamaran and its competitors gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Catamaran N/A N/A 37.48
Catamaran Competitors $50.73 billion $1.52 billion 9.92

Catamaran’s competitors have higher revenue and earnings than Catamaran. Catamaran is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Catamaran and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Catamaran 0 0 0 0 N/A
Catamaran Competitors 81 944 1506 28 2.58

As a group, “Managed Health Care” companies have a potential downside of 2.67%. Given Catamaran’s competitors higher possible upside, analysts clearly believe Catamaran has less favorable growth aspects than its competitors.

Insider and Institutional Ownership

90.6% of shares of all “Managed Health Care” companies are held by institutional investors. 2.6% of shares of all “Managed Health Care” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Catamaran has a beta of -0.18, indicating that its share price is 118% less volatile than the S&P 500. Comparatively, Catamaran’s competitors have a beta of 0.70, indicating that their average share price is 31% less volatile than the S&P 500.


Catamaran competitors beat Catamaran on 7 of the 9 factors compared.

Catamaran Company Profile

Catamaran Corporation (Catamaran) is a provider of pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefit management industry. The Company operates in two segments: PBM and HCIT. The Company offers PBM services, which are marketed under the Catamaran PBM brand, and is engaged in owning and operating a network of mail and specialty pharmacies. In addition, the Company is a national provider of drug benefits to its customers under the federal government’s Medicare Part D program. The Company’s HCIT product offerings include a range of software products for managing prescription drug programs and for drug prescribing and dispensing. The Company’s customers include organizations in the pharmaceutical supply chain, such as pharmacy benefit managers, managed care organizations, self-insured employer groups, unions, third-party healthcare plan administrators, and state and federal government entities.

Receive News & Ratings for Catamaran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catamaran and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply